Bausch + Lomb shares rose 2.3% in pre-market activity following the release of second-quarter 2026 results announced before the market opened. The global eye health company reported revenue of $1.39 billion, outpacing the analyst consensus of $1.37 billion and representing a 9% increase over the same quarter a year earlier. Adjusted earnings per share of $0.15 were in line with expectations.
Alongside the quarterly figures, management raised its full-year 2026 revenue guidance to a range of $5.44 billion to $5.54 billion, with the midpoint moving slightly above prior analyst expectations. That guidance update, combined with the top-line beat, formed a central part of the positive investor reaction.
Profitability improvements underpinned the upbeat tone. Operating income reached $83 million for the quarter, a reversal from an operating loss of $11 million in Q2 2025. Cash flow from operations climbed sharply to $153 million, up from $35 million a year earlier. Adjusted EBITDA rose by $50 million year-over-year to $241 million, reflecting the broader improvement in underlying business performance.
The company-specific results stood out in the context of a broadly muted U.S. equity market. The S&P 500 was up around 0.2% while the Dow Jones was slightly lower, indicating that Bausch + Lomb’s move was largely driven by its own results rather than macro market momentum. Sector peers had already delivered solid top-line expansion during this earnings season, which may have helped set expectations for healthcare equipment stocks and primed investors to reward Bausch + Lomb’s outturn.
Analyst activity added another constructive element. UBS initiated coverage with a Buy rating ahead of the report, contributing to a total of six buy recommendations among analysts covering the stock. That increase in favorable analyst coverage was highlighted as a supportive factor heading into the earnings release.
In combination, the clean revenue beat, the raised full-year revenue outlook, and a substantial year-over-year swing in operating profitability contributed to the pre-market share uptick. Investors appeared to respond to evidence that operational performance is improving and cash generation is strengthening.
Market context - key figures:
- Q2 revenue: $1.39 billion (consensus $1.37 billion; +9% year-over-year)
- Adjusted EPS: $0.15 (matched estimates)
- Full-year 2026 revenue guidance: $5.44 billion to $5.54 billion (midpoint above prior analyst expectations)
- Operating income: $83 million (vs. operating loss of $11 million in Q2 2025)
- Cash flow from operations: $153 million (vs. $35 million year-ago)
- Adjusted EBITDA: $241 million (up $50 million year-over-year)